 |
|
|
|
 |
|
|
| Article 1 to 9 out of 9 concerning Biotec Pharmacon ASA
|
-
Svein Lien appointed new CEO of Biotec Pharmacon ASA
(12 Mar 2010)
Svein Lien has been appointed new CEO of Biotec Pharmacon, following Lars Viksmoen's decision to resign after 3 years as CEO. Svein Lien will assume the position with effect from 15 March, 2010.Svein Lien (55) joins the company with a financial ...
-
Biotec Pharmacon: Phase III results with SBG for diabetic foot ulcer not positive
(24 Nov 2009)
Biotec Pharmacon has received the results from both its phase III studies with SBG for diabetic foot ulcer and regrets to inform that the results are not positive. The studies failed to show superiority of SBG vs. placebo in terms of ulcer healing, ...
-
Jan Buch Andersen heading up newly established Biotec Marine Biochemicals AS
(18 Jun 2009)
Biotec Pharmacon ASA has moved all its enzyme activities into Biotec Marine Biochemicals AS and hired Jan Buch Andersen as Managing Director of the newly established subsidiary. The target is to strengthen the development of the marine enzymes ...
-
Biotec Pharmacon: Phase III diabetic ulcer program proceeds as planned after interim analysis
(15 May 2009)
The independent statistician responsible for the interim analysis of the second of the two phase III studies with SBG for diabetic foot ulcers recommends that Biotec Pharmacon proceeds as planned with the study. As no adjustments are being made to ...
-
Biotec Pharmacon's SBG shows promising effect in animal model for inflammatory bowel disease
(27 Mar 2009)
Researchers at Rikshospitalet University Hospital has presented an abstract from an animal study with SBG for treatment of inflammatory bowel disease on the 3rd World Immune Regulation Meeting in Davos, Switzerland. The study demonstrated that ...
-
Biotec Pharmacon: Patient inclusion started in phase III Oral Mucositis study
(20 Oct 2008)
Patient inclusion has commenced as planned in the first of two phase III studies for the use of Biotec Pharmacon's SBG in patients with oral mucositis. This is a common and potentially severe side-effect of radiotherapy for cancer, in particular for ...
-
Immunocorp Animal Health AS secures major research contract
(18 Aug 2008)
Immunocorp Animal Health AS (IAH), a wholly owned subsidiary of Biotec Pharmacon ASA, has been awarded a major research and development contract by the European Commission. The contract will be undertaken by nine partners from Norway, the ...
-
New clinical study for treatment of diabetic foot ulcers
(28 Feb 2006)
Biotec Pharmacon has entered into an agreement with Nottingham City Hospital NHS Trust to perform a clinical phase II study entitled "A randomised, double-blind, placebo-controlled study to determine the efficacy of soluble beta-1,3/1,6-glucan in ...
-
Biotech Pharmacon to trial SBG/Rituxan combination therapy with Radium
(06 Dec 2005)
Latest beta-glucan/cancer antibody study follows Herceptin
Biotec Pharmacon and the Norwegian Rikshospitalet - Radiumhospitalet TRUST (Department for Clinical Cancer Research) have signed a Letter of Intent to perform clinical studies to evaluate the efficacy and safety of the company's pharmaceutical ...
Additional information
Biotec Pharmacon ASA
Tromsų, Norway
Company
|
|
|
|
|
|
Top
